• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Immediate and antecedent causes of mortality in hospitalised Indian patients with COVID-19.印度新冠肺炎住院患者死亡的直接和先前原因。
Bioinformation. 2022 Apr 30;18(4):402-410. doi: 10.6026/97320630018402. eCollection 2022.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性(COVA 研究):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
4
Characteristics, outcomes, and mortality amongst 133,589 patients with prevalent autoimmune diseases diagnosed with, and 48,418 hospitalised for COVID-19: a multinational distributed network cohort analysis.133589例确诊为COVID-19的自身免疫性疾病患者及48418例因COVID-19住院患者的特征、结局和死亡率:一项跨国分布式网络队列分析
medRxiv. 2020 Nov 27:2020.11.24.20236802. doi: 10.1101/2020.11.24.20236802.
5
Colchicine for the treatment of COVID-19.秋水仙碱治疗 COVID-19。
Cochrane Database Syst Rev. 2021 Oct 18;10(10):CD015045. doi: 10.1002/14651858.CD015045.
6
Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.挪威 2019 年冠状病毒病(NO COVID-19)实用开放性标签研究,评估硫酸羟氯喹在 2019 年冠状病毒病中度重症住院患者中的早期使用:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 5;21(1):485. doi: 10.1186/s13063-020-04420-0.
7
Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.皮下注射沙利鲁单抗治疗中重度 COVID-19 感染住院患者与标准治疗(SARCOVID)的比较:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Sep 9;21(1):772. doi: 10.1186/s13063-020-04588-5.
8
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.新冠康复者血浆或超免疫球蛋白用于新冠患者:快速综述
Cochrane Database Syst Rev. 2020 May 14;5(5):CD013600. doi: 10.1002/14651858.CD013600.
9
Association of underlying comorbidities and progression of COVID-19 infection amongst 2586 patients hospitalised in the National Capital Region of India: a retrospective cohort study.印度国家首都地区 2586 名住院患者的基础合并症与 COVID-19 感染进展的关联:一项回顾性队列研究。
Mol Cell Biochem. 2023 Jan;478(1):149-160. doi: 10.1007/s11010-022-04485-2. Epub 2022 Jun 25.
10
Atorvastatin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection: A structured summary of a study protocol for a randomised controlled trial.阿托伐他汀和阿司匹林作为 SARS-CoV-2 感染患者的辅助治疗:一项随机对照试验的研究方案的结构化总结。
Trials. 2020 Oct 30;21(1):902. doi: 10.1186/s13063-020-04840-y.

引用本文的文献

1
The impact of Covid-19 in Chhattisgarh, India: A descriptive study.新冠疫情对印度恰蒂斯加尔邦的影响:一项描述性研究。
J Family Med Prim Care. 2024 Jan;13(1):221-229. doi: 10.4103/jfmpc.jfmpc_1012_23. Epub 2024 Feb 8.

本文引用的文献

1
Biological attributes of age and gender variations in Indian COVID-19 cases: A retrospective data analysis.印度新冠肺炎病例中年龄和性别差异的生物学特征:一项回顾性数据分析。
Clin Epidemiol Glob Health. 2021 Jul-Sep;11:100788. doi: 10.1016/j.cegh.2021.100788. Epub 2021 May 28.
2
First and second waves of coronavirus disease-19: A comparative study in hospitalized patients in Reus, Spain.新冠肺炎疫情的第一波和第二波:西班牙雷乌斯住院患者的对比研究。
PLoS One. 2021 Mar 31;16(3):e0248029. doi: 10.1371/journal.pone.0248029. eCollection 2021.
3
A Retrospective Observational Study to Determine the Early Predictors of In-hospital Mortality at Admission with COVID-19.一项回顾性观察研究,以确定COVID-19入院时院内死亡的早期预测因素。
Indian J Crit Care Med. 2020 Dec;24(12):1174-1179. doi: 10.5005/jp-journals-10071-23683.
4
Clinical characteristics and fatal outcomes of hypertension in patients with severe COVID-19.严重 COVID-19 患者的高血压临床特征和致死结局。
Aging (Albany NY). 2020 Nov 16;12(23):23436-23449. doi: 10.18632/aging.104019.
5
Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study.成人因冠状病毒 19 住院和死亡风险的生存风险预测算法(QCOVID):全国推导和验证队列研究。
BMJ. 2020 Oct 20;371:m3731. doi: 10.1136/bmj.m3731.
6
Demographic perspectives on the mortality of COVID-19 and other epidemics.人口统计学视角下的 COVID-19 和其他传染病的死亡率。
Proc Natl Acad Sci U S A. 2020 Sep 8;117(36):22035-22041. doi: 10.1073/pnas.2006392117. Epub 2020 Aug 20.
7
Extrapulmonary manifestations of COVID-19.COVID-19 的肺外表现。
Nat Med. 2020 Jul;26(7):1017-1032. doi: 10.1038/s41591-020-0968-3. Epub 2020 Jul 10.
8
Clinical characteristics of 82 cases of death from COVID-19.COVID-19 死亡 82 例的临床特征。
PLoS One. 2020 Jul 9;15(7):e0235458. doi: 10.1371/journal.pone.0235458. eCollection 2020.
9
Coronavirus Disease 2019 (COVID-19): A Short Review on Hematological Manifestations.2019冠状病毒病(COVID-19):血液学表现的简要综述
Pathogens. 2020 Jun 20;9(6):493. doi: 10.3390/pathogens9060493.
10
Hematological features of persons with COVID-19.新型冠状病毒肺炎患者的血液学特征。
Leukemia. 2020 Aug;34(8):2163-2172. doi: 10.1038/s41375-020-0910-1. Epub 2020 Jun 11.

印度新冠肺炎住院患者死亡的直接和先前原因。

Immediate and antecedent causes of mortality in hospitalised Indian patients with COVID-19.

作者信息

Keerthi B Y, Saritha K, Shah Chirali, Thomas Vimala, Cheryala Vikram

机构信息

Department of General Medicine, Telangana Institute of Medical Sciences and Research, Gachibowli, Hyderabad, India, 500032.

Department of Family Medicine, Telangana Institute of Medical Sciences and Research, Gachibowli, Hyderabad, India, 500032.

出版信息

Bioinformation. 2022 Apr 30;18(4):402-410. doi: 10.6026/97320630018402. eCollection 2022.

DOI:10.6026/97320630018402
PMID:36909696
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9997491/
Abstract

It is of interest to assess the immediate and antecedent causes of mortality amongst adult COVID-19 infected patients with or without comorbidities admitted in an exclusive COVID-19 hospital was conducted the between August 2020 to May 2021. The immediate and antecedent causes were collected from the medical certificate of cause of death (MCCD). Remaining data was extracted from the hospital's record. ICMR protocol was used to grade severity of illness at admission into mild, moderate and severe categories. Clinical status during hospitalisation and most recent radiographic and laboratory data were used to assess disease progression and outcome. This study includes data from 571 people, who died at our centre between August 2020 and May 2021. Patients registered without any co-morbidity were 146 with mean age of 57.53 years; (33/146) were females and (110/46) males. Hypertension (274, 47.99%) was found in a moderately large number of patients followed by diabetes (225, 39.4%) and anaemia (199, 34.6%). Increase in risk of mortality of COVID-19 was found maximum in patients with acute respiratory distress syndrome (72.33%), followed by secondary infections (6.83%). Mortality recorded in this study was mainly in males of older age (50 years and above) with at least one co-morbidity. Anaemia was also prevalent amongst these patients and considered as an independent factor for mortality. Hence, recording of comorbidities and haemoglobin levels may help as a guideline to develop risk stratification and management of patients with COVID-19 to reduce overall mortality.

摘要

对2020年8月至2021年5月期间入住一家专门的新冠肺炎医院的成年新冠肺炎感染患者(无论有无合并症)的直接和先前死亡原因进行评估很有意义。直接和先前原因从死亡医学证明书(MCCD)中收集。其余数据从医院记录中提取。采用印度医学研究理事会(ICMR)方案将入院时的疾病严重程度分为轻度、中度和重度。住院期间的临床状况以及最新的影像学和实验室数据用于评估疾病进展和结局。本研究纳入了2020年8月至2021年5月期间在我们中心死亡的571人的数据。登记无任何合并症的患者有146人,平均年龄为57.53岁;女性33人(/146),男性110人(/46)。发现相当多的患者患有高血压(274例,47.99%),其次是糖尿病(225例,39.4%)和贫血(199例,34.6%)。新冠肺炎死亡风险增加在急性呼吸窘迫综合征患者中最高(72.33%),其次是继发感染(6.83%)。本研究记录的死亡主要发生在年龄较大(50岁及以上)且至少有一种合并症的男性中。贫血在这些患者中也很普遍,并被视为死亡的独立因素。因此,记录合并症和血红蛋白水平可能有助于作为制定新冠肺炎患者风险分层和管理的指南,以降低总体死亡率。